Reassortant hexavalent rotavirus vaccine - Sinovac Biotech
Latest Information Update: 14 May 2024
At a glance
- Originator Sinovac Biotech
- Class Attenuated vaccines; Rotavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Rotavirus infections
Most Recent Events
- 27 Mar 2024 Phase-I clinical trials in Rotavirus infections (Prevention, In adults, In children, In infants) in China (PO) before March 2024
- 31 Jan 2024 Preclinical trials in Rotavirus infections (Prevention) in China (PO) before January 2024
- 11 Jan 2024 National Medical Products Administration approves regulatory application for Reassortant hexavalent rotavirus vaccine in Rotavirus infections